OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-24.99%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$160M
AUM Growth
+$160M
(-33%)
Cap. Flow
-$22.8M
Cap. Flow
% of AUM
-14.22%
Top 10 Holdings %
Top 10 Hldgs %
42.9%
Holding
67
New
14
Increased
18
Reduced
12
Closed
15
Top Buys
| 1 |
Agios Pharmaceuticals
AGIO
|
$4.26M |
| 2 |
CMRX
Chimerix, Inc.
CMRX
|
$3.45M |
| 3 |
TVRD
Tvardi Therapeutics, Inc. Common Stock
TVRD
|
$2.66M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
$2.59M |
| 5 |
ADMS
Adamas Pharmaceuticals, Inc.
ADMS
|
$2.46M |
Top Sells
| 1 |
RLYP
RELYPSA INC COM
RLYP
|
$6.24M |
| 2 |
CEMP
Cempra, Inc.
CEMP
|
$6.23M |
| 3 |
Supernus Pharmaceuticals
SUPN
|
$4.5M |
| 4 |
Tonix Pharmaceuticals
TNXP
|
$4.33M |
| 5 |
AVGR
Avinger, Inc. Common Stock
AVGR
|
$4.32M |
Sector Composition
| 1 | Healthcare | 77.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CLLS
51
Cellectis
CLLS
$265M
| – | – |
-50,000
| Closed | -$1.55M |
|
52
MacroGenics
MGNX
$122M
| – | – |
-35,000
| Closed | -$1.08M |
|
53
Neurocrine Biosciences
NBIX
$13.9B
| – | – |
-55,000
| Closed | -$3.11M |
|
54
Sangamo Therapeutics
SGMO
$165M
| – | – |
-60,000
| Closed | -$548K |
|
|
AVGR
55
DELISTED
Avinger, Inc. Common Stock
AVGR
| – | – |
-190,000
| Closed | -$4.32M |
|
|
AGRX
56
DELISTED
Agile Therapeutics, Inc
AGRX
| – | – |
-300,000
| Closed | -$2.93M |
|
|
ALDR
57
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| – | – |
-65,000
| Closed | -$2.15M |
|
|
CEMP
58
DELISTED
Cempra, Inc.
CEMP
| – | – |
-200,000
| Closed | -$6.23M |
|
|
VTAE
59
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| – | – |
-58,500
| Closed | -$1.06M |
|
|
RLYP
60
DELISTED
RELYPSA INC COM
RLYP
| – | – |
-220,000
| Closed | -$6.24M |
|
|
LJPC
61
DELISTED
La Jolla Pharmaceutical Company
LJPC
| – | – |
-140,000
| Closed | -$3.78M |
|
|
62
Tonix Pharmaceuticals
TNXP
$246M
| – | – |
-565,000
| Closed | -$4.33M |
|